Phase Ib Study of the Safety of T-DXd and Durvalumab With Chemotherapy in Advanced or Metastatic HER2+ Non-squamous NSCLC
Status:
Recruiting
Trial end date:
2024-02-12
Target enrollment:
Participant gender:
Summary
DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in
combination with durvalumab and chemotherapy in patients with HER2 positive advanced and
metastatic non-small cell lung cancer. The efficacy will be also analyzed as a secondary
endpoint.